Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The development of a clinical trial protocol and functional biomarkers for age-related macular degeneration

McKeague, Claire 2014. The development of a clinical trial protocol and functional biomarkers for age-related macular degeneration. MPhil Thesis, Cardiff University.
Item availability restricted.

[img]
Preview
PDF - Accepted Post-Print Version
Download (4MB) | Preview
[img] PDF - Supplemental Material
Restricted to Repository staff only

Download (987kB)

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness amongst older adults in the developed world. With the predicted rise in the ageing population over the next decades, the prevalence of this debilitating disease will simply continue to increase. The only treatments currently available are for advanced neovascular AMD. The retina is already severely compromised by this stage in disease development. Therefore, there is a pressing need to evaluate potential novel interventions that aim to prevent the development of advanced disease in people with early AMD, to prevent sight loss from occurring. Furthermore, it is necessary to develop tests that are sensitive to subtle changes in visual function in order to evaluate the efficacy of these emerging treatments. There is a growing body of evidence to suggest that hypoxia contributes to the development of AMD. Hypoxia is most acute at night when the retinal photoreceptors are most metabolically active, due to the demands of the rod dark current. Increasing the light levels at night will cause the oxygen demand, and hence the hypoxia, to be substantially diminished. This leads to the hypothesis that providing low level night time light therapy to people with early AMD may slow disease progression by reducing hypoxia. In order to evaluate the potential effectiveness of such an intervention, it is necessary to select appropriate outcome measures. The inherent variability of the standard test of visual function, visual acuity, renders it inappropriate for use as a primary outcome measure in proof of concept clinical trials. Therefore, the first aim of this thesis was to evaluate the diagnostic validity and repeatability of alternative functional tests that may be used as biomarkers for early macular disease. Dark adaptation was evaluated using three stimuli, a spot of 2o radius and annuli of 7o and 12o radii, in 21 healthy adults (on two occasions) and in 11 participants with early AMD. All stimuli were found to be highly diagnostic for early AMD. The spot of 2o radius provided the best separation between groups with respect to the time constant of cone recovery (area under the ROC curve 0.91). The repeatability of chromatic and flicker thresholds were also assessed in 30 healthy adults. The coefficient of repeatability, expressed as a percentage of the mean threshold, was 17.1% for red-green chromatic thresholds, 31.1% for blue-yellow, 53.4% for 14Hz flicker thresholds, and ranged between 36.4%-53.3% for parameters of dark adaptation. A small learning effect was found for both chromatic thresholds and the 14-Hz flicker test, indicating that a control group is needed in studies of new therapeutic interventions. The second aim of this thesis was to develop a protocol for a clinical trial that seeks to determine if low level night time light therapy can prevent the progression of early AMD. The level of retinal illuminance required to suppress the rod dark current, the maximum retinal illuminance which prevents substantial suppression of melatonin secretion, and the most appropriate means of delivering the dose of retinal illumination were evaluated. The final protocol employed an organic LED illuminated light mask, worn during hours of sleep, as the mode of intervention. In conclusion, this thesis has confirmed that cone dark adaptation is a sensitive functional biomarker for AMD, and that all three functional tests have a good inter-session repeatability. These biomarkers will be validated in the prospective clinical trial of low-level light therapy to confirm their prognostic and predictive capabilities. The proposed trial will also evaluate the effectiveness of the low level night time light therapy, delivered by means of an illuminated light mask, at slowing the progression of early AMD.

Item Type: Thesis (MPhil)
Status: Unpublished
Schools: Optometry and Vision Sciences
Subjects: R Medicine > RE Ophthalmology
Uncontrolled Keywords: Age-related macular degeneration; hypoxia; biomarker; repeatability; colour vision; flicker; dark adaptation
Date of First Compliant Deposit: 30 March 2016
Last Modified: 19 Mar 2016 23:51
URI: http://orca.cf.ac.uk/id/eprint/68916

Actions (repository staff only)

Edit Item Edit Item